Business
Therma Bright Receives Positive Notification from U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming days Toronto, Ontario--(N...
About this update from Therma Bright Inc.
[{"type":"text","content":"\nTherma Bright Receives Positive Notification from U.S. DHHS's Centers for Medicare & Medicaid (CMS)Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming daysToronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (\"Therma\" or the \"Company\"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide a quick update from a recent notification from US Department of Health and Huma Services' (DHHS) Centers of Medicare and Medicaid (CMS). CMS has informed the Company of the pending permanent Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes for its Venowave VW5 device; anticipating notification and approval in the coming days.The CMS's CPT® and HCPCS codes are expected to cover ten (10) health related and CMS reimbursable indications, which offers a great opportunity in the marketplace for the Company, its customers, reseller partners and shareholders. CMS will be publishing the final determinations for the 1st Biannual HCPCS Level II on this site: HCPCS Level II Coding Decisions.The ten (10) indications include:Prevention of deep vein thrombosis (DVT)Management of the symptoms of post-thrombotic syndrome (PTS)Prevention of primary thrombosisTreatment of lymphedemaDiminishing post-operative pain and swellingTreatment of leg swelling due to vascular insufficiencyTreatment of varicose veinsTreatment of chronic venous insufficiencyEnhancing blood circulationTreatment of intermittent claudicationAs shared in prior releases, the Centers for Disease Control and Prevention (CDC) estimates that over 900,000 U.S. citizens are impacted by deep vein thrombosis (DVT) and pulmonary embolism (PE) alone each year. And ResearchAndMarkets global research and MarketDigital research both projected the deep vein thrombosis global market alone to reach between USD $1.26 billion by 2028 and USD 1.554 billion by 2032, respectively. \"We're patiently awaiting confirmation from CMS, which is expected in a matter of days,\" shared Rob Fia, CEO of Therma Bright. \"And we plan to make the announcement and all the details around the permanent codes immediately upon receipt of this formal approval.\"About Therma Bright Inc.Therma Bright is a developer an...